NASDAQ:IMVT
Immunovant, Inc. Stock News
$31.48
+0.550 (+1.78%)
At Close: May 16, 2024
SHAREHOLDER ALERT: Investigation of Immunovant Announced by Holzer & Holzer, LLC
12:32pm, Tuesday, 02'nd Feb 2021
Atlanta, Georgia--(Newsfile Corp. - February 2, 2021) - Holzer & Holzer, LLC is investigating whether Immunovant, Inc. (NASDAQ: IMVT) ("Immunovant" or the "Company") complied with federal securities l
Why Mustang Bio, Phathom Pharma And More Are Moving Today
11:37am, Tuesday, 02'nd Feb 2021
Mustang Bio (NASDAQ: MBIO) shares are trading higher after the company announced the FDA has lifted the clinical hold for its pivotal phase 2 MB-107 clinical trial. The company plans to enroll the fir
Immunovant stock loses half its value after pausing dosing in trial of thyroid eye disease treatment
08:29am, Tuesday, 02'nd Feb 2021
Shares of Immunovant Inc. plunged 49.8% to pace all premarket losers Tuesday, after the biopharmaceutical company said it has paused dosing in its phase 2b trial for IMVT-1401, a treatment for thyroid
Immunovant Announces Voluntary Pause in Clinical Dosing of IMVT-1401
06:30am, Tuesday, 02'nd Feb 2021
NEW YORK, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today announce
Immunovant: IMVT-1401's Indication Expansion, $444M In Cash And New Management
02:34am, Thursday, 14'th Jan 2021
Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on monoclonal antibody therapeutic development for autoimmune diseases. Immunovant has a one product pipeline (IMVT-1401) across
Immunovant Appoints Rita Jain Chief Medical Officer And Provides Corporate Update
05:00pm, Tuesday, 12'th Jan 2021
NEW YORK, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today announce
Completed SPAC Mergers 2020: 10 Top Performing SPACs of the Year
12:10pm, Monday, 21'st Dec 2020
There has been plenty of completed SPAC merger news in 2020 as more companies use it to go public and we're looking at the top performers. The post Completed SPAC Mergers 2020: 10 Top Performing SPACs
Immunovant Up On Data, And Other News: The Good, Bad And Ugly Of Biopharma
06:37pm, Thursday, 27'th Aug 2020
Immunovant stock shoots up on positive trial data news. REGENXBIO received FDA approval for Phase II trial of RGX-314.
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) OmniAb® partner Immunovant, Inc. (NASDAQ: IMVT) announced positive topline results from ASCEND MG,
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 19)
10X Genomics Inc (NASDAQ: TXG)
ALX Oncology Holdings Inc (NASDAQ: ALXO)
Avenue Therapeutics Inc (NASDAQ: ATXI)...
Why Immunovant Could Benefit From The J&J-Momenta Deal
12:00am, Wednesday, 19'th Aug 2020
Immunovant Inc (NASDAQ: IMVT) shares were ripping higher Wednesday in a sympathy move.
What Happened: Shares of New York-based Immunovant, which focuses on treatment for...
Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors o
Immunovant Reports Financial Results for the Quarter Ended June 30, 2020
08:01pm, Wednesday, 12'th Aug 2020
NEW YORK, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today re
The Greatest SPAC Winners - From Nikola To DraftKings And Virgin Galactic
09:48am, Monday, 13'th Jul 2020
Newly de-SPACed companies fight against headwinds. 10 companies that overcame the long odds.
Did Hedge Funds Make The Right Call On Immunovant, Inc. (IMVT) ?
03:12pm, Sunday, 12'th Jul 2020
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and succes
